{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:34:35Z","timestamp":1757543675242},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.mehy.2017.09.021","type":"journal-article","created":{"date-parts":[[2017,9,24]],"date-time":"2017-09-24T14:31:29Z","timestamp":1506263489000},"page":"53-55","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A unique and promising combination of medications for the treatment of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"109","author":[{"given":"James D.","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2017.09.021_b0005","doi-asserted-by":"crossref","unstructured":"Iturrid-Medina Y, Sotero R, Toussant P, Mateos-Perez J, Evans A, and the Alzheimer\u2019s Disease Neuroimaging Institute. Early Role of Vascular Disc Regulation on Late Onset Alzheimer\u2019s Disease based on multifactorial date driven analysis. Nature Communications. 7:11934 (2\/16).","DOI":"10.1038\/ncomms11934"},{"issue":"1","key":"10.1016\/j.mehy.2017.09.021_b0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/ph3010158","article-title":"Oxidative stress induced mitochondrial failure and vascular hypoperfusion as a key initiator for the development of alzheimer\u2019s disease","volume":"3","author":"Aliev","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.mehy.2017.09.021_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mehy.2003.12.045","article-title":"A \u201cmitochondrial cascade hypothesis\u201d for sporadic Alzheimer\u2019s disease","volume":"63","author":"Swerdlow","year":"2004","journal-title":"Med Hypotheses"},{"issue":"3","key":"10.1016\/j.mehy.2017.09.021_b0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol"},{"key":"10.1016\/j.mehy.2017.09.021_b0025","first-page":"125","article-title":"Phosphorylated TDP-43 in Alzheimer\u2019s Disease and dementia with Lewy bodies","volume":"11","author":"Tetsuaki","year":"2009","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.mehy.2017.09.021_b0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4161\/cam.3.1.7402","article-title":"Oxidative stress in Alzheimer's disease","volume":"3","author":"Gella","year":"2009","journal-title":"Cell ADH MIGR"},{"issue":"4","key":"10.1016\/j.mehy.2017.09.021_b0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1474-9728.2004.00101.x","article-title":"How chronic inflammation can affect the brain and support the development of Alzheimer\u2019s disease in old age: the role of microglia and astrocytes","volume":"3","author":"Blasco","year":"2004","journal-title":"Aging Cell"},{"key":"10.1016\/j.mehy.2017.09.021_b0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000117279","article-title":"European pentoxifylline multi-infarct dementia study","volume":"36","author":"Bayer","year":"1996","journal-title":"Eur Neurol"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2017.09.021_b0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0009-8981(00)00327-2","article-title":"Evidence that pioglitazone metformin and pentoxifylline are inhibitors of glycation","volume":"301","author":"Rahbar","year":"2000","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.mehy.2017.09.021_b0050","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/infdis\/166.4.847","article-title":"Cytokines release from migroglia differential inhibition by pentoxifylline and dexamethasone","volume":"166","author":"Choa","year":"1992","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.mehy.2017.09.021_b0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00044011-200828090-00001","article-title":"Theraputic use of nicergeline","volume":"28","author":"Winblad Fioravanti","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.mehy.2017.09.021_b0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.brainres.2005.10.050","article-title":"Positive effects of nicergeline against neuronal cell death induced by activated microglia and astrocytes","volume":"1066","author":"Mizuno","year":"2005","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.mehy.2017.09.021_b0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1532-5415.1989.tb05494.x","article-title":"Nicergeline in mild to moderate dementia. A multi-centered double-blind placebo-controlled study","volume":"37","author":"Battaglia","year":"1989","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.mehy.2017.09.021_b0070","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1096\/fj.07-9610com","article-title":"Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways","volume":"22","author":"Atamma","year":"2008","journal-title":"FASEB J"},{"issue":"20","key":"10.1016\/j.mehy.2017.09.021_b0075","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer\u2019s disease-like tau aggravations by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.mehy.2017.09.021_b0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00109-013-1112-3","article-title":"Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance","volume":"92","author":"Lonskaya","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.mehy.2017.09.021_b0085","unstructured":"Moussa M et al. Cancer drug restores brain dopamine, reduces toxic proteins in Parkinson dementia. Drug-Improved-Cognition-and-Motor-Skills-in-Small-Parkinson\u2019s-Clinical-Trial at the Society for Neuroscience annual meeting in October 2015."},{"issue":"15","key":"10.1016\/j.mehy.2017.09.021_b0090","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00018-005-5082-7","article-title":"Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage","volume":"62","author":"Voziyan","year":"2005","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.mehy.2017.09.021_b0095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jalz.2009.07.038","article-title":"Current Alzheimer\u2019s disease clinical trials: methods and placebo outcomes","volume":"5","author":"Schneider","year":"2009","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.mehy.2017.09.021_b0100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/WAD.0b013e318194a324","article-title":"Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale","volume":"23","author":"Xie","year":"2009","journal-title":"Alz Dis Assoc Dis"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987717309787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987717309787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T22:30:30Z","timestamp":1570141830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987717309787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":20,"alternative-id":["S0306987717309787"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2017.09.021","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A unique and promising combination of medications for the treatment of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2017.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}